| 5425 |
Centers for Disease Control and Prevention |
Html |
en |
WARNING: Cigarettes cause fatal lung disease. |
null |
| right web address | 0.987879 |
| Español | 0.403508 |
| Language Assistance | 0.712207 |
| Português | 0.391584 |
| Kreyòl Ayisyen | 0.700648 |
| Instructions | 0.282468 |
| different file formats | 0.919531 |
| Tiếng Việt | 0.70734 |
| Deutsch | 0.348548 |
| help | 0.283342 |
|
| РуÑ?Ñ?кий | 0.283258 |
| Polski | 0.39029 |
| Tagalog | 0.362008 |
| options | 0.298124 |
| Français | 0.385004 |
| Downloading Viewers | 0.795919 |
| العربية | 0.436655 |
| information | 0.283148 |
| page | 0.385868 |
|
CLICK HERE |
| 7058 |
Centers for Disease Control and Prevention |
Html |
en |
Global Health - Honduras |
CDC in Honduras addresses HIV/AIDS, tuberculosis, emerging infectious diseases, influenza, and field epidemiology training. |
| Central America | 0.555545 |
| CDC | 0.684534 |
| endorsement | 0.439919 |
| infectious diseases | 0.546937 |
| Epidemiology Training Program | 0.720498 |
| public health institutions | 0.6907 |
| sentinel surveillance units | 0.659122 |
| local health staff | 0.643051 |
| epidemiologists | 0.449114 |
| preparation | 0.420919 |
| Content source | 0.529745 |
| HHS | 0.443436 |
| Notice | 0.426496 |
| basic-level field epidemiology | 0.727671 |
| alliances | 0.435156 |
| field epidemiology training | 0.93161 |
|
| Download Overview Fact | 0.649996 |
| technical skills | 0.537988 |
| public health burdens | 0.692058 |
| standard operating procedures | 0.645483 |
| HIV/AIDS | 0.427696 |
| advanced-level | 0.444575 |
| tuberculosis | 0.435822 |
| priority | 0.432974 |
| flu | 0.432179 |
| non-federal site | 0.556115 |
| San Pedro Sula | 0.674393 |
| intermediate-level field epidemiology | 0.750057 |
| Tegucigalpa | 0.453701 |
| region | 0.421519 |
| employees | 0.420119 |
|
CLICK HERE |
| 7812 |
Centers for Disease Control and Prevention |
Html |
en |
Radiation - Health Communication |
Gateway to Health Communication and Social Marketing Practice - Radiation |
| severe retinal burns | 0.513352 |
| terrorist event range | 0.529573 |
| nuclear detonation | 0.491582 |
| radioactive waste | 0.485649 |
| mental retardation | 0.470403 |
| national emergency-response plan | 0.511917 |
| large quantity | 0.465442 |
| extended period | 0.467215 |
| following precautionary measures | 0.506805 |
| bone marrow depletion | 0.502084 |
| great public alarm | 0.502786 |
| extremely large doses | 0.53871 |
| nuclear bomb | 0.516791 |
| exposure | 0.571501 |
| External exposure | 0.501362 |
| radioactive materials | 0.492781 |
| external radiation | 0.538092 |
| terrorist nuclear attack | 0.523719 |
| bodily injury | 0.465788 |
| health effects | 0.645985 |
| nuclear facility | 0.521052 |
| large region | 0.465275 |
| lower doses | 0.477527 |
| high levels | 0.471532 |
| blast site | 0.478901 |
|
| radioactive fallout | 0.490281 |
| electrical power | 0.471747 |
| adverse health effects | 0.637533 |
| severe skin burns | 0.514334 |
| internal exposure | 0.505988 |
| great psychological effects | 0.518635 |
| cause extensive contamination | 0.533197 |
| radioactive material | 0.633571 |
| acute radiation syndrome | 0.976989 |
| potential exposure | 0.495575 |
| large enough dose | 0.465572 |
| public health official | 0.509967 |
| radioactive contaminated material | 0.561532 |
| public health | 0.512188 |
| smaller doses | 0.48308 |
| major event | 0.465349 |
| small nuclear device | 0.620009 |
| beneficial uses | 0.470675 |
| people | 0.496637 |
| blast | 0.486333 |
| greater opportunity | 0.466252 |
| extreme cases | 0.467809 |
| dirty bomb | 0.521648 |
| Routine exposure | 0.496526 |
|
CLICK HERE |
| 7839 |
Centers for Disease Control and Prevention |
Html |
en |
Blindness - Health Communication |
Blindness and Vision Impairment - Gateway to Health Communication - CDC |
| assistive devices | 0.353043 |
| unrestricted driver | 0.374489 |
| major blinding eye | 0.997287 |
| irreversible visual impairment | 0.579699 |
| peripheral vision | 0.392 |
| associated costs | 0.34761 |
| insurance coverage | 0.351868 |
| corrective action | 0.349852 |
| federal government | 0.540648 |
| ethnic groups | 0.347932 |
| vision impairment | 0.939349 |
| productive life | 0.347886 |
| age-related macular degeneration | 0.841555 |
| working-age adults | 0.362503 |
| early treatment | 0.347079 |
| contact lenses | 0.383327 |
| U.S. population ages | 0.47014 |
| standard glasses | 0.384026 |
| blindness | 0.881825 |
| social interactions | 0.346874 |
| blood vessels | 0.485625 |
| better eye | 0.543914 |
| small blood vessels | 0.483171 |
| sharp central vision | 0.53049 |
| diabetic retinopathy | 0.890631 |
|
| low-income families | 0.35031 |
| Blind people | 0.367249 |
| Legal blindness | 0.729694 |
| worse vision | 0.417268 |
| severe vision impairment | 0.685268 |
| optic nerve | 0.355209 |
| residual vision | 0.387832 |
| environmental modifications | 0.348305 |
| best correction | 0.381561 |
| visual field | 0.381363 |
| vision rehabilitation | 0.387263 |
| daily activities | 0.519825 |
| blinding eye diseases | 0.986569 |
| tiny blood vessels | 0.480638 |
| retina | 0.399255 |
| everyday activities | 0.378355 |
| visually impaired people | 0.47367 |
| higher risk | 0.573828 |
| precise functional impairment | 0.637411 |
| Social Security disability | 0.480436 |
| personal income | 0.352784 |
| disability benefits | 0.530384 |
| vision loss | 0.379935 |
| blindness rises | 0.50982 |
|
CLICK HERE |
| 8099 |
Centers for Disease Control and Prevention |
Html |
en |
Opioids drive continued increase in drug overdose deaths |
[Title] |
| educational programs | 0.271041 |
| CDC’s National | 0.276604 |
| research letter | 0.274572 |
| public insurance programs | 0.390935 |
| state-run health plans | 0.320072 |
| drug class | 0.284018 |
| prescription drug abuse | 0.460015 |
| Disease Control | 0.274952 |
| monitoring patients | 0.267506 |
| behavioral health | 0.270889 |
| federal government | 0.267109 |
| overdose deaths | 0.960226 |
| health care providers | 0.428586 |
| prescription drugs | 0.327926 |
| prescription drug | 0.586635 |
| opioid labeling | 0.323675 |
| steady rise | 0.267921 |
| CDC Director Tom | 0.328966 |
| compensation programs | 0.267211 |
| prescription drug monitoring | 0.428394 |
| state licensing boards | 0.311976 |
| Health Statistics | 0.276823 |
| multiple cause-of-death file | 0.322761 |
| high doses | 0.266204 |
|
| substance abuse treatment | 0.313318 |
| chronic pain management | 0.310855 |
| multiple times | 0.265049 |
| prescription opioid abuse | 0.413699 |
| United States | 0.406803 |
| anti-anxiety drugs | 0.291567 |
| CDC researchers | 0.276668 |
| antipsychotic drugs | 0.288282 |
| overdose deaths increase | 0.609417 |
| effective pain treatment | 0.30752 |
| death certificates | 0.264789 |
| drug overdose deaths | 0.843826 |
| pharmaceutical drugs | 0.291017 |
| opioid analgesics | 0.469284 |
| similar increase | 0.265438 |
| prescription drug overdose | 0.509777 |
| pharmaceutical overdose deaths | 0.821829 |
| abuse-deterrent opioid formulations | 0.381168 |
| prescription painkillers | 0.313581 |
| drug monitoring programs | 0.395779 |
| opioid therapy | 0.326822 |
| improper patient | 0.264658 |
| mental health conditions | 0.331373 |
| predominant role | 0.270234 |
|
CLICK HERE |
| 9080 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Researchers Highlight Lessons Learned from H3N2v, July 2011-April 2012 |
CDC Researchers Highlight Lessons Learned from H3N2v, July 2011-April 2012. |
| variant influenza viruses | 0.708011 |
| Clinical Infectious Diseases | 0.927793 |
| public health interventions | 0.63148 |
| mathematical models | 0.542516 |
| human cases | 0.567529 |
| H3N2v | 0.995868 |
| Dr. David Swerdlow | 0.640468 |
| H3N2v virus | 0.592409 |
| low levels | 0.549929 |
| young children | 0.553823 |
| pandemic influenza preparedness | 0.682897 |
| cross-reactive antibody | 0.549611 |
| age distribution changes | 0.648038 |
| H3N2v modeling studies | 0.693393 |
| modeling studies | 0.801003 |
| age distribution | 0.729729 |
| H3N2v illness | 0.596334 |
| highest risk | 0.544039 |
| public health strategies | 0.632912 |
| older children | 0.546919 |
| influenza outbreak | 0.611311 |
| journal Clinical Infectious | 0.690585 |
| H3N2v infections | 0.680057 |
| H3N2v cases | 0.697359 |
| influenza-like illness | 0.543244 |
|
| swine exposure | 0.691165 |
| ongoing relevant insight | 0.678055 |
| limited person-to-person transmission | 0.683339 |
| H3N2v infection | 0.594972 |
| large H3N2v outbreak | 0.712826 |
| care outbreaks | 0.552519 |
| polymerase chain reaction | 0.660361 |
| previously reported infections | 0.69075 |
| Dr. Lyn Finelli | 0.640521 |
| H3N2v transmission | 0.599796 |
| CDC studies | 0.59537 |
| CDC scientists | 0.565764 |
| influenza surveillance data | 0.701393 |
| costly control measures | 0.629771 |
| medical care | 0.540636 |
| Epperson et | 0.570343 |
| serologic studies | 0.557804 |
| minimal swine | 0.561283 |
| mitigating influenza illness | 0.677969 |
| mathematical model | 0.666624 |
| Infectious Diseases website | 0.638072 |
| larger H3N2v outbreak | 0.726558 |
| H3N2v outbreak | 0.809535 |
| H3N2v outbreaks | 0.629739 |
|
CLICK HERE |
| 9185 |
Centers for Disease Control and Prevention |
Html |
en |
MMWR News Synopsis: July 14, 2011 |
MMWR News Synopsis: July 14, 2011 |
| motion picture companies | 0.67309 |
| average number | 0.429246 |
| methyl bromide | 0.956388 |
| Camp owners/managers | 0.423612 |
| average decrease | 0.512857 |
| outbreak investigation | 0.423613 |
| postfumigation methyl bromide | 0.700134 |
| Prevent Disease Associated | 0.502133 |
| methyl bromide levels | 0.696108 |
| youth smoking initiation | 0.541499 |
| virus endemic areas | 0.522962 |
| youth-rated movie | 0.429885 |
| dengue virus | 0.728613 |
| febrile illness | 0.414228 |
| mosquitoes-transmitted virus | 0.426364 |
| published policies | 0.422102 |
| CDC Division | 0.807324 |
| dengue fever | 0.549815 |
| major motion picture | 0.523311 |
| appropriate mosquito-avoidance strategies | 0.511316 |
| excessive methyl bromide | 0.684579 |
| causative agent | 0.418452 |
| appropriate strategies | 0.412599 |
| laboratory-confirmed dengue virus | 0.662704 |
| environmental exposures | 0.42005 |
|
| onscreen tobacco | 0.444141 |
| United States | 0.53092 |
| infected calves | 0.425438 |
| dengue outbreaks | 0.547803 |
| methyl bromide exposures | 0.814318 |
| Electronic Media | 0.793854 |
| National Cancer Institute | 0.540355 |
| appropriate mosquito-avoidance practices | 0.512497 |
| parasite Cryptosporidium | 0.466588 |
| causal relationship | 0.42881 |
| downward trend | 0.429224 |
| potential hazardous exposure | 0.501805 |
| methyl bromide-fumigated commodities | 0.594827 |
| dengue risks | 0.542469 |
| staff members | 0.498473 |
| motion picture company | 0.525196 |
| independent motion picture | 0.523173 |
| fumigation measures | 0.413565 |
| Alcohol-based hand sanitizers | 0.503585 |
| youth-rated movies | 0.423827 |
| pretravel knowledge | 0.416575 |
| tobacco incidents | 0.679378 |
| accessible handwashing stations | 0.492738 |
| infected persons | 0.428692 |
|
CLICK HERE |
| 10121 |
Centers for Disease Control and Prevention |
Html |
en |
Overview of the Family Smoking Prevention and Tobacco Control Act |
null |
| free giveaways | 0.255666 |
| cultural events | 0.25474 |
| place specific restrictions | 0.31071 |
| Tobacco Control Act | 0.969284 |
| machine sales* | 0.258124 |
| harm claims | 0.252506 |
| FDA authority | 0.395418 |
| ingredient levels | 0.249913 |
| adult-only facilities | 0.260389 |
| processing facilities | 0.249755 |
| moist snuff | 0.257245 |
| retail outlets | 0.24949 |
| smokeless tobacco package | 0.476106 |
| certain tobacco products | 0.437514 |
| risk tobacco product | 0.445919 |
| tobacco products | 0.78568 |
| tobacco-brand sponsorships | 0.256062 |
| user fee | 0.247215 |
| Bans cigarettes | 0.25515 |
| detailed information | 0.251157 |
| tribal governments | 0.250333 |
| Family Smoking Prevention | 0.30963 |
| sample cigarettes | 0.259844 |
| certain classes | 0.248648 |
| healthier future | 0.312567 |
|
| United States | 0.249286 |
| landmark law | 0.252425 |
| provisions ban | 0.270774 |
| smokeless tobacco packaging | 0.475348 |
| tobacco company owners | 0.438195 |
| nicotine yields | 0.253755 |
| public health | 0.406157 |
| marketing tobacco products | 0.490223 |
| warning label statements | 0.299807 |
| principal sides | 0.250752 |
| entire law | 0.24782 |
| smokeless tobacco packages | 0.479391 |
| tobacco companies | 0.425598 |
| comprehensive guide | 0.24969 |
| smokeless tobacco | 0.595205 |
| non-tobacco promotional items | 0.301567 |
| Tobacco Control Act. | 0.440144 |
| specific respects | 0.252317 |
| entertainment events | 0.254803 |
| Ban face-to-face sales | 0.297548 |
| Funds FDA regulation | 0.336331 |
| U.S. market share | 0.289277 |
| health risks | 0.25313 |
| particular category | 0.248428 |
|
CLICK HERE |
| 10330 |
Centers for Disease Control and Prevention |
Html |
en |
HAN Archive - 00352'Health Alert Network (HAN) |
Health Alert Network (HAN). Provided by the Centers for Disease Control and Prevention (CDC). |
| multiple specimens | 0.442091 |
| CDC | 0.944267 |
| symptom onset | 0.567966 |
| Respiratory Syndrome Coronavirus | 0.883798 |
| MERS-CoV | 0.705974 |
| Disease Control | 0.443503 |
| MERS-CoV testing | 0.611635 |
| Interim Surveillance Recommendations | 0.513244 |
| state health departments | 0.563424 |
| novel coronavirus | 0.49117 |
| new guidance states | 0.561763 |
| infection preventionists | 0.457201 |
| case definitions | 0.431964 |
| Lower respiratory specimens | 0.599585 |
| World Health Organization | 0.594307 |
| CDC rRT-PCR assay | 0.679475 |
| primary care physicians | 0.543337 |
| public health risks | 0.588092 |
| health update | 0.456941 |
| Contact your state | 0.434643 |
| case definition | 0.435712 |
| PM ET | 0.44424 |
| health department laboratories | 0.528397 |
| East Respiratory Syndrome | 0.831608 |
|
| intensive care physicians | 0.538118 |
| CDC’s Interim | 0.595177 |
| CDC Health Alert | 0.807003 |
| Human Infection | 0.438315 |
| probable case | 0.645515 |
| Testing Clinical Specimens | 0.551568 |
| United States | 0.550458 |
| interim guidance | 0.462599 |
| respiratory pathogens | 0.605635 |
| contact CDC | 0.598332 |
| state health department | 0.814458 |
| laboratory-confirmed cases | 0.455411 |
| local health departments | 0.75544 |
| CDC’s MERS | 0.619185 |
| acute respiratory illness | 0.793517 |
| MERS-CoV cases | 0.491048 |
| Middle East Respiratory | 0.831683 |
| United Arab Emirates | 0.537434 |
| emergency departments | 0.436323 |
| MERS-CoV case | 0.488877 |
| MERS-CoV infection | 0.674144 |
| common respiratory pathogens | 0.598061 |
| previous guidance | 0.458583 |
| infectious disease specialists | 0.540405 |
|
CLICK HERE |
| 12468 |
Centers for Disease Control and Prevention |
Video |
en |
June 2013 ACIP Meeting -- Opening Remarks |
Opening remarks for June 2013 The U.S. Advisory Committee of Immunization Practices meeting hosted by Dr. Jon Temte and Dr. Larry Pickering.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at: http://streaming.cdc.gov/vod.php?id=6d1740eceeb88604b828ba9580b53bc620130730140231828 |
|
|
CLICK HERE |